| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/19/2004 | WO2003088979A3 Oligonucleotides from sequences coding for the surface component of envelope proteins of primate t-cell leukaemia/lymphoma viruses (ptlv) and uses thereof |
| 02/19/2004 | WO2003087318A3 Truncated 24 kda basic fibroblast growth factor |
| 02/19/2004 | WO2003080640B1 Lymphatic and blood endothelial cell genes |
| 02/19/2004 | WO2003075850A9 Methods for alzheimer's disease treatment and cognitive enhancement |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065882A3 Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003059255A3 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/19/2004 | WO2003048193A3 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003045398A8 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 02/19/2004 | WO2003035104B1 Compositions and methods for selected tumor treatment |
| 02/19/2004 | WO2003034028A3 Methods for identifying and using modulators of estrogen related receptor gamma |
| 02/19/2004 | WO2003032907A3 High-concentration protein formulations and method of manufacture |
| 02/19/2004 | WO2003024402A3 Lpa receptor agonists and antagonists and methods of use |
| 02/19/2004 | WO2003018770A3 Amplified oncogenes and their involvement in cancer |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2003008537A9 Epitope sequences |
| 02/19/2004 | WO2003000113A9 Compositions and methods for the diagnosis and treatment of tumor |
| 02/19/2004 | WO2002091991A3 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 02/19/2004 | WO2002091989A3 Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
| 02/19/2004 | WO2002090514A8 Epidermal growth factor receptorantisense oligonucleotides |
| 02/19/2004 | WO2002083866A3 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| 02/19/2004 | WO2002081496A3 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
| 02/19/2004 | WO2002078613A3 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response |
| 02/19/2004 | WO2002076380A3 Cytotoxic factors for modulating cell death |
| 02/19/2004 | WO2002074251A3 Monoclonal antibody therapy for pancreas cancer |
| 02/19/2004 | WO2002070023A3 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 02/19/2004 | WO2002066498A3 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 02/19/2004 | WO2002064214A8 Anti cancer combination of substituted pyrroles and paclitaxel |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002037113A3 Clinical and functional validation of targets from disseminated cancer cells |
| 02/19/2004 | WO2002032920A3 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| 02/19/2004 | WO2002032429A3 Use of inhibitors of progesterone receptor for treating cancer |
| 02/19/2004 | WO2002030356A3 Synthesis of epothilones and relates analogs |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034242 Compounds containing a specific branched chain end terminal group, which is isopropyl, sec.-butyl, or tert.-butyl; a polar leading group, and long chain aliphatic, non-cyclic, saturated or nonsaturated linking groups |
| 02/19/2004 | US20040034231 Amidinophenyl-4-aminoacetic acid derivative is useful for treating diseases such as thrombosis, apoplexy, cardiac infarction, inflammation and arteriosclerosis, which are associated with coagulation factors xa, IXa and thrombin |
| 02/19/2004 | US20040034230 Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions; anticarcinogenic agent |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034216 A gonane ring or with the nitrogen forming a heterocyclic structure; antiinflammation agents, antitumor agents; treating asthma, allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, AIDS, arrhythmias |
| 02/19/2004 | US20040034202 Ketone spirocyclopropaneindene compounds; antineoplastic agents to inhibit tumor cell growth in vitro or in vivo; particularly effective against solid tumors and multi-drug resistant tumors |
| 02/19/2004 | US20040034103 Cdc25 photophatase inhibitors |
| 02/19/2004 | US20040034095 Low toxicity; side effect reduction |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034084 Side effect reduction; for treatment of AIDS, cancer and arthritis |
| 02/19/2004 | US20040034082 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases |
| 02/19/2004 | US20040034081 Estrogen receptor modulators |
| 02/19/2004 | US20040034078 Such as 2-(2-butylamino-ethylsulfanylmethyl)-1H-benzimidazole-4-carboxylic acid amide for treatment of cancer, strokes, head trauma, and neurodengenerative diseases; solid phase synthesis |
| 02/19/2004 | US20040034072 Aza-amino acid derivatives (factor Xa inhibitors 15) |
| 02/19/2004 | US20040034052 Antitumor agents |
| 02/19/2004 | US20040034051 Phenanthridine derivatives and antitumoral medicaments containing phenanthridine |
| 02/19/2004 | US20040034050 Homo-camptothecin derivatives |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034040 E.g., 5-(4-(3-chloro-4-methoxybenzylamino)-5,6,7,8-tetra-hydro-1-benzothieno(2,3 -d) pyrimidin-2-yl)valeric acid to treat high pullmonary pressure; hypotensive agents; liver, cardiovascular, kidney and sexual disorders; antiallergens |
| 02/19/2004 | US20040034038 E.g., N-(2-(benzyl(2-hydroxyethyl)amino)-5-bromophenyl)-N'-(5-cyano-2- pyrazinyl)urea; anticarcinoma, -tumor, -proliferative and -metastatic agents; angiogenesis inhibition |
| 02/19/2004 | US20040034034 Novel piperazine derivatives |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034023 Dibenzophenanthrolines useful for treating cancer |
| 02/19/2004 | US20040034022 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 02/19/2004 | US20040034020 A purine deriveative, useful for treatment of inflammatory conditions, immune disorders, tissue injury, infections, and cancer |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034005 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 02/19/2004 | US20040034003 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033977 Oligonucleotide modulation of cell adhesion |
| 02/19/2004 | US20040033964 For treating atheroma, tumors and other neoplastic tissue; treating atherosclerotic inflammation |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033935 Novel imidazole derivatives, production method thereof and use thereof |
| 02/19/2004 | US20040033932 Myc targets |
| 02/19/2004 | US20040033542 Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer |
| 02/19/2004 | US20040033526 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033519 Binary or polynary targeting and uses thereof |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033491 Proteins and nucleic acids encoding same |
| 02/19/2004 | US20040033282 Kefir extract as anti-cancer agent |
| 02/19/2004 | US20040033281 Extracts of cacao and cacao bean husk with inhibitory effects on carcinogenesis |
| 02/19/2004 | US20040033231 First domain comprising a PP14 polypeptide sequence and a second domain comprising a polypeptide sequence of the Fc region of an immunoglobulin protein; treatment of immune system diseases and disorders |
| 02/19/2004 | US20040033229 PSMA antibodies and protein multimers |
| 02/19/2004 | US20040033211 Antigen arrays for treatment of bone disease |
| 02/19/2004 | US20040033197 Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts |
| 02/19/2004 | DE10233500A1 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel and its use as a medicament |
| 02/19/2004 | CA2818693A1 Methods and compositions concerning poxviruses and cancer |
| 02/19/2004 | CA2495935A1 Screening strategy for anticancer drugs |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495489A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
| 02/19/2004 | CA2495487A1 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| 02/19/2004 | CA2495085A1 Diagnosis and treatment of tuberous sclerosis |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |